Aurobindo Pharma informs about disclosure

05 Oct 2024 Evaluate

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015, Aurobindo Pharma has informed that Aurogen South Africa (Pty), (Aurogen) a wholly owned step-down subsidiary of the Company in South Africa, has entered into an agreement with Rene Glyne Family trust to sell and dispose of the entire 24.5% shares held by Aurogen. After the disposal of 24.5% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen BBBEE Invest Co (Proprietary). The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July 2023, is enclosed as ‘Annexure’.

The above information is a part of company’s filings submitted to BSE.


Aurobindo Pharma Share Price

1172.30 -7.95 (-0.67%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×